Consequences of bias and imprecision in measurements of glucose and Hba1c for the diagnosis and prognosis of diabetes mellitus

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 65, Issue 240, 2005, Pages 51-60

  Petersen, Per Hyltoft ^a   Jørgensen, Lone G M ^b   Brandslund, Ivan ^b   De Fine Olivarius, Niels ^c   Stahl, Marta ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b LILLEBAELT HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Analytical quality specifications; Biological set point; Biological within subject variation; Criteria for diagnosis of diabetes; Risk of retinopathy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE COURSE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NORMAL DISTRIBUTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY CONTROL; RISK ASSESSMENT; ACCURACY; CONFIDENCE INTERVAL; MEASUREMENT; RISK FACTOR; ARTICLE; BLOOD; EPIDEMIOLOGY; RISK;

BIAS (EPIDEMIOLOGY); BLOOD GLUCOSE; CONFIDENCE INTERVALS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PROGNOSIS; RISK;

EID: 23744474804     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510500236135     Document Type: Conference Paper

References (15)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the expert committee on the diagnosis and classi-fication of diabetes mellitus. Diabetes Care 1997; 20:1183-97
2. Stahl M, Jørgensen LGM, Hyltoft Petersen P, Brandslund I, de Fine Olivarius N, Borch-Johnsen K. Optimization of preanalytical condi-tions and analysis of plasma glucose. 1. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61:169-80.
3. Jørgensen LGM, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. Plasma glucose reference interval in a low-risk population 2. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61:181-190.
4. Hyltoft Petersen P, Brandslund I, Jørgensen LGM, Stahl M, de Fine Olivarius N, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glu-cose as the basis for analytical quality specifica-tions in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61:191-204.
5. Stahl M, Brandslund I, Jørgensen LGM, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. Can capillary whole blood glucose and ve-nous plasma glucose measurements be used in-terchangeably in diagnosis of diabetes mellitus? Scand J Clin Lab Invest 2002; 62:159-66.
6. Jørgensen LGM, Brandslund I, Stahl M, Hyltoft Petersen P, Iversen S, Klitgaard N, de Fine Oli-varius N. Upper reference limit, analytical qual-ity specifications and clinical use of haemoglo-bin A1C. Scand J Clin Lab Invest 2002; 62:609-22.
7. Jørgensen LGM, Brandslund I, Hyltoft Petersen P, de Fine Olivarius N, Stahl M. The effect of the new ADA and WHO guidelines on the num-ber of diagnosed cases of diabetes mellitus. Clin Chem Lab Med 2003; 41:1246-50.
8. Hyltoft Petersen P, Fraser CG, Kaliner A, Kenny D (eds). Strategies to Set Global Analytical Quality Specifications in Laboratory Medicine. Scan J Clin Lab Invest 1999; 59:475-585.
9. Jørgensen LGM, Hyltoft Petersen P, Brandslund I. The impact of variability in the risk of disease exemplified by diagnosing diabetes mellitus based on ADA and WHO criteria as gold stan-dard. Int. J Risk Assessment and Management 2005; in press.
10. http://www.westgard.com/guest17.htm
11. http://www.westgard.com/guest26.htm
12. von Eyben FE, Hyltoft Petersen P, Blaabjerg O, Lindegaard Madsen E. Analytical quality speci-fications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin Chem Lab Med 1999; 37:553-61.
13. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44:968-83.
14. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. BMJ 2000; 321:405-12
15. Fraser CG. Interpretation of clinical chemistry laboratory data. Blackwell Scientific Publica-tions. Oxford Edinburgh London Boston Palo Alto Melbourne 1986. 179 pp.